Novo Nordisk
NVO
#107
Rank
NZ$304.70 B
Marketcap
NZ$69.13
Share price
-2.70%
Change (1 day)
-18.50%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): NZ$6.88

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is NZ$7.21. In 2025 the company made an earnings per share (EPS) of NZ$6.49 an increase over its 2024 EPS that were of NZ$5.98.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.886.06%
2025NZ$6.498.48%
2024NZ$5.98
2016NZ$2.04

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$1.30-82.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$56.47 682.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.62-49.81%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
NZ$8.26 14.55%๐Ÿ‡บ๐Ÿ‡ธ USA